1. Perhimpunan Dokter Paru Indonesia (PDPI). PPOK (Penyakit Paru Obstruksi Kronik), pedoman praktis diagnosis dan penatalaksanaan di Indonesia; 2004
2. D’Urzo AD, De Salvo MC, Ramierez-Rivera A, Almeida J, Sichletidis L, Rapatz G et al. in patients with COPD, treatment with a combination of Formoterol and Ipratropium is more effective than a combination of Salbutamol and ipratropium, a 3-week, Randomized, double-blind, within-patient, multicenter study. Chest 2001; 119:1347-1356
3. Devereux G. ABC of chronic obstructive pulmonary disease, definition, epidemiology, and risk factors. Available from www.BMJ.com. Accessed on March 2008
4. Pusdalin-IDI. FK UI tambah dua guru besar. Available from www.idionline.org/katagori/infoo_profesi/313. Accessed on April 2008
5. Partodimulyo AP, Mangunnegoro H, Yunus F, Hartono S. Penilaian kualiti hidup dengan menggunakan St George’s Respiratory Questionnaire (SGQR) pada penderita PPOK yang mendapatkan pengobatan agonis β2 dibandingkan dengan kombinasi agonis β2 + antikolinergik. J Respir Indo 2006; 26:11-18
6. Anthonisen N, Boule M. Pharmacologic management of stable COPD. In: Bourbeau J, Nault D, Borycki E, eds. Comprehensive management of COPD. London: BC Decker;
2002.65-78
7. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to sameterol plus fluticasone in moderate COPD. Chest 2008; 134:255-262 8. Groneberg F, Fischer A, Welte T. Fixed combination therapies in COPD-effect on quality
life. Int J Chron Obstruct Pulmon Dis 2007; 2(4):551-557
9. Hanania NC, Darken P, Horstman D, Reisner C, Lee B, Davis S et al. The efficacy and safety of fluticasone propionat (250 mg)/salmeterol(50 mg) combined in the diskus inhaler for the treatment of COPD. Chest 2003; 124:834-843
10. Rodrigo GJ, Nannini LJ, Rodri’guez-Roisin R. Safety of long-acting β2-agonist in stable COPD. Chest 2008; 133:1079-1087
11. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; updated 2009
12. Montes de osca M. Chronic obstructive pulmonary disease: definition guidelines, and severity staging. Respir med. 2007 ; 3:7-11
13. Pauwels RA, Buits A, Calverley PMA, Jenkins JR, Hurds SS. Global strategy for diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease, NHLB/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD), workshop summary. Am J Respir Crit Med 2001; 163:1256-1276
14. Borbeau J, Siok M, Nault D, Borycki E. Optimizing medical care delivery. In: Bourbeau, Nault, Borycki, eds. Comphrehensive management of Chronic Obstructive Pulmonary Disease. Ontario: BC Decker Inc; 2002.1-16
15. Perhimpunan Dokter Paru Indonesia (PDPI). PPOK (Penyakit Paru Obstruksi Kronik), pedoman praktis diagnosis dan penatalaksanaan di Indonesia; 2001
16. Maranatha D. Penyakit paru obstruksi kronik (PPOK). In: Asalgaff H, Wibisono MJ, Winariani, eds. Buku ajar penyakit paru. Surabaya: Gramik FK Unair; 2004.29-41
17. Donnell RO, Breen D, Wilson S, Djukanovic R. Inflammatory cells in the airways in copd.
Thorax 2006: 61;448-454
18. Petty TL. Chronic obstructive pulmonary disease. In: Henley ME, Welsh CH, eds. Lange current diagnosis and treatment in pulmonary medicine. USA: McGraw-Hill companies;
2003.82-90
19. Kardos P, Keenan. Tackling COPD: a multicomponent disease driven by inflammation.
MedGenMed 2006; 8(3):54
20. Agusti A. Systemic effects of chronic obstructive pulmonary disease, what we know and what we don’t know (but should). Proc Am Thorac Soc 2007; 4:522-525
21. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary (2001)
22. McIvor A, Lowry J, Borbeu J, Borycky E. Assessment of COPD. In: Bourbeau J, Nault D, Borycki E, eds. Comprehensive management of COPD. London: BC Decker; 2002.19-32 23. Jones PW, Harding G, Berry P, Wiklund, Chen WH, Leidy K. Development and first
validation of the copd assessment test. Eur Respir J 2009; 34:648-654
24. Terzano C, Petroianni A, Ricci A, Allegra A. Combination therapy in COPD: different response of COPD stages and predictivity of functional parameters. Eur rev medi pharmacol sci 2005; 9:209-215
25. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125:249-259
26. Cazzola M, Dahl R. Inhaled combination therapy with long-acting β2-agonist and corticosteroids in stable COPD. Chest 2004; 126:220-237
27. Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P. Early onset of effect of salmeterol and fluticasone propionat in chronic obstructive pulmonary disease. Thorax 2005; 60:301-304
28. Ziment I. Drug used in respiratory care. In: Burton GG, Hodgkin JE, Ward JJ, eds.
Respiratory care a guide to clinical practice. California: Lippincott; 2001(4).469-496 29. Medical look. Salmeterol review. Available from
http://www.medical-look.com/reviews/salmeterol.html. Accessed on April 2009
30. Lau R. Salmeterol : the optimization of an asthmatic drug. Available from http://cosmo.ucdavis.edu/archives/2008/cluster8/lau-ryan.pdf. Accesssed on July 2008
31. Pharmacy and Drugs. Fluticasone propionat. Available from http://chemicalland21.com/lifescience/phar/fluticasonepropionat.html. Accessed on October 2009
32. Sanders A. Corticosteroids in lung diseases. In: Lin AN, Paget SA, eds. Principles of corticosteroid therapy. London: Arnold; 2002.272-278
33. Adcock IM, Ito K. Glucocortikoid pathways in chronic obstructive pulmonary disease therapy. Proc Am Thorac Soc 2005; 2:313-319
34. Sin DD, Paul Man SF, Marciniuk DD, Ford G, FitzGerald M, Wong E et al. The effect of fluticasone with or without salmeterol on systemic biomarkers of inflammation in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2008; 177:1207-1214
35. Zeng J, Yang L, Wu Y, Chen P, Wen Z, Huang W et al. The efficacy and safety of combination salmeterol(50µg)/fluticasone propionat(500µg) inhalation twicw daily via accuhaler in Chinese patients with COPD. Chest 2007; 132:1756-1763
36. Chung KF. Salmeterol/flutikason combination in the treatment of COPD.
Int J Chron Obstruct Pulmon Dis 2006; 1(3):235–242
37. Dahlan MS. Konsistensi V menentukan jumlah sampel. In: Langkah-langkah membuat proposal penelitian bidang kedokteran dan kesehatan. Jakarta: Sagung Seto; 2008.61-76 38. Abidin A, Yunus F, Wiyono W, Ratnawati A. Manfaat rehabilitasi paru dalam
meningkatkan atau mempertahankan kapasitas fungsional dan kualitas hidup pasien penyakit paru obstruktif kronik di RSUP Persahabatan. J Respir Indo 2009; 29:70-78
39. Soemarwoto R, Manuhutu E, Mangunnegoro H, Setiawati A, Yunus F, Yusuf Anwar.
Pengaruh suplementasi Phyllanthus niruri L pada penderita PPOK eksaserbasi akut yang mendapat siprofloksasin. J Respir Indo 2006; 26:34-35
40. Soecher J, Dutton T, Bourbeu J. Program evaluation and outcome measurement. In:
Bourbeu J, Nault D, Borycki E, eds. Comprehensive management of Chronic Obstruktive Pulmonary Disease. London: BC Decker Inc;2002.357-358
41. Caverley PM, Anderson JA, Celli B, Ferguson C, Jenkins C, Jones PW et al. Salmeterol and flutikason propionat and survival in obstructive pulmonary disease. N Engl J Med 2007; 356:775-789